Distributor inventory | Tablet

Type 2 diabetes mellitus: to improve blood glucose control when diet and exercise are not enough; used alone or along with other antidiabetic medicines

Vildagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1, GIP), leading to increased insulin release and reduced glucagon after meals. Metformin reduces glucose production in the liver and improves insulin sensitivity, lowering blood glucose without usually causing hypoglycaemia when used alone.

Tablet for oral use. Take exactly as prescribed, usually with meals to reduce stomach upset. Swallow whole with water; do not crush/chew if it is an SR/ER tablet. Maintain diet/exercise and monitor blood sugar regularly.

Nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, metallic taste, headache, dizziness, tremor (especially with other antidiabetics), upper respiratory tract infection, hypoglycaemia (when combined with insulin/sulfonylurea), rash

Not for type 1 diabetes or diabetic ketoacidosis. Metformin may rarely cause lactic acidosis—risk increases with kidney disease, dehydration, severe infection, heart/lung failure, heavy alcohol intake, or older age; stop and seek care if rapid breathing, severe weakness, abdominal pain, or unusual drowsiness occur. Check renal function before and during therapy; avoid/use with caution in moderate-to-severe renal impairment. Vildagliptin: monitor liver enzymes; discontinue if jaundice or persistent elevated transaminases occur. Temporarily stop metformin around iodinated contrast studies or major surgery as advised by doctor. Use caution in pancreatitis history; stop if severe persistent abdominal pain. Long-term metformin may cause vitamin B12 deficiency—periodic monitoring may be needed.

Alcohol (increases lactic acidosis risk), iodinated contrast media, carbonic anhydrase inhibitors (e.g., topiramate, acetazolamide), cimetidine, diuretics, corticosteroids, thyroid hormones, sympathomimetics, beta-agonists, antipsychotics, oral contraceptives, ACE inhibitors (may enhance glucose-lowering), insulin and sulfonylureas (increased hypoglycaemia risk); drugs affecting renal function may increase metformin levels

Store below 25°C in a cool, dry place. Protect from moisture and direct light. Keep out of reach of children.

Galvus Met 50/500 Tablet, Zomelis Met 50/500 Tablet, Jalra M 50/500 Tablet, Vildamet 50/500 Tablet, Vildar-M 50/500 Tablet